No Prescription |
 |
 | ||
|
DA Double Advantage For Dogs 4kg to 10kg K9 Advantix 55 |
|
| ||
No Prescription » Prescription Drugs 5 » DA Double Advantage For Dogs 4kg to 10kg K9 Advantix 55 For The Prevention And Treatment Of Ticks Fleas Mosquitoes Biting Flies And Lice On Dogsü£ Repels and kills ticks including Deer ticks (vector of Lyme disease) American dog ticks (vector of Rocky Mountain spotted fever) Brown dog ticks (vector of ehrlichiosis) and Lone Star ticks (vector of ehrlichiosis) for up to four weeksü£ Kills fleas on dogs within 12 hours and continues to prevent infestations for a monthü£ Repels and kills fleas before they lay eggsü£ Larval flea stages in the dog's surroundings are killed following contact with a Imidacloprid/Permethrin treated dogü£ Repels and kills mosquitoes for up to four weeksü£ Repels and prevents blood-feeding by biting fliesü£ Waterproofü£ Remains effective after bathing and swimmingü£ 5-way protection (against fleas ticks biting flies mosquitoes and lice) Buy DA Double Advantage For Dogs 4kg to 10kg K9 Advantix 55 and other Prescription Drugs 5 products online at Medstore. Buy Online at Medstore - Click Here!
About DA Double Advantage For Dogs 4kg to 10kg K9 Advantix 55: Product Type: Prescription Drugs 5 DA Double Advantage ( For Dogs upto 4kg ) (K9 Advantix 55 Generic Imidacloprid/Permethrin) DA Double Advantage (For Dogs 4kg to 10kg K9 Advantix 55 Generic Imidacloprid/Permethrin) For Dogs 4kg to 10kg K9 Advantix 55 Generic Imidacloprid/Permethrin For 4kg - 10kg 1.0ml X 3 pipettes For 4kg - 10kg 1.0ml X 9 pipettes For Over 25kg 4.0ml X 3 pipettes For Over 25kg 4.0ml X 6 pipettes For Over 25kg 4.0ml X 12 pipettes For upto 4kg 0.4mL x 3 Pipettes For upto 4kg 0.4ml X 9 pipettes For Dogs 4kg to 10kg K9 Advantix 55 Generic Imidacloprid/Permethrin DA Double Advantage
View more Prescription Drugs 5 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
